Latest Articles

BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer - The Manila Times

BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer The Manila Times

In recurrent endometrial cancer, BioNTech drug held off progression 8 months - Stock Titan

In recurrent endometrial cancer, BioNTech drug held off progression 8 months Stock Titan

Progesterone in MHT for Protection Against Endometrial Cancer - The Vajenda

Progesterone in MHT for Protection Against Endometrial Cancer The Vajenda

THE RIGHT TO REST: WHY SOUTH AFRICAN WOMEN SHOULD GET MENSTRUAL LEAVE - PressReader

THE RIGHT TO REST: WHY SOUTH AFRICAN WOMEN SHOULD GET MENSTRUAL LEAVE PressReader

Magnetic Resonance Imaging as a Non-Surgical Predictor of Endometriosis Fertility Index Surgical Factors.

Endometriosis affects 6%-10% of women of reproductive age and is associated with chronic pelvic pain, infertility, and impaired quality of life. The endometriosis fertility index (EFI) predicts spontaneous pregnancy postoperatively, …

Knowing Before Cutting: How Preoperative Algorithmic Stratification Can Transform Surgical Planning in Endometriosis.

USWNT boss Emma Hayes opens up on handling pressure and living with endometriosis - MSN

USWNT boss Emma Hayes opens up on handling pressure and living with endometriosis MSN

Menstrual Disorders Reducing Women’s Productivity, Experts Raise Alarm - freedomonline.com.ng

Menstrual Disorders Reducing Women’s Productivity, Experts Raise Alarm freedomonline.com.ng

Prince Harry sued by charity he set up in Africa to honor late mother Princess Diana - 13newsnow.com

Prince Harry sued by charity he set up in Africa to honor late mother Princess Diana 13newsnow.com

Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as Highly Expressed, Clinically Relevant Target for Gynecologic Cancers - National Today

Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as Highly Expressed, Clinically Relevant Target for Gynecologic Cancers National Today